Earli, a Redwood City, CA-based biotechnology company that developed a novel approach to early cancer detection with a synthetic targeting platform, received an investment from Accenture through Accenture Ventures.
The amount of the deal was not disclosed.
The company intends to use the funds to expand collaborations with global health and pharma companies that can use its technology to detect and treat cancer.
Led by CEO Cyriac Roeding, Earli aims to transform cancer into a benign experience by solving one of the most difficult challenges in oncology: reliably distinguishing between healthy and cancerous cells. Its approach uses programmable genetic constructs that react and signal the presence of active cancer cells at an early stage. The synthetic biopsy approach enhances the sensitivity and specificity of cancer detection for an earlier diagnosis, allowing pharmaceutical and biotech companies to create personalized treatments more quickly and often at a lower cost.
